Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 1 · Recruiting · Familial Adenomatous Polyposis
Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsPhase 1 · Recruiting · Head and Neck Squamous Cell Carcinoma (HNSCC)
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesPhase 1 · Recruiting · Relapsed or Refractory B-cell Malignancies
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerPhase 1 · Recruiting · Unresectable
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsPhase 1 · Recruiting · Solid Tumor
REC-7735 in Participants With Solid TumorsPhase 1 · Recruiting · Solid Tumors
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/recursion-pharmaceuticals-inc/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.